IP Library Granted Patent US 7,138,386
Granted Patent B2
US 7,138,386 · App. 10/250,373 · Granted Nov 21, 2006

Preventives or remedies for arthritis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,138,386
App. No.
10/250,373
Granted
Nov 21, 2006
Kind
B2
Abstract

The present invention relates to pharmaceuticals, foods and drinks, food additives, animal feeds and feed additives comprising an N-acylated hydroxyproline derivative or a salt thereof, and an amino sugar or a salt thereof and/or a glycosaminoglycan or a salt thereof as active ingredients, use of an Nacylated hydroxyproline derivative or a salt thereof for the production of an arthritis preventing or treating agent, and a method for preventing or treating arthritis which comprises administering an N-acylated hydroxyproline derivative or a salt thereof, and an amino sugar or a salt thereof and/or a glycosaminoglycan or a salt thereof.

Claims (24)

1. A pharmaceutical composition which comprises an N-acylated hydroxyproline derivative or a salt thereof, an amino sugar or a salt thereof, and a glycosaminoglycan or a salt thereof.

2. The pharmaceutical composition according to claim 1 , wherein said hydroxyproline is selected from the group consisting of cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and trans-3-hydroxy-D-proline.

3. The pharmaceutical composition according to claim 1 or 2 , wherein the acyl moiety of said N-acylated hydroxyproline derivative is an acyl group having 2–23 carbon atoms.

4. The pharmaceutical composition according to claim 3 , wherein said N-acylated hydroxyproline derivative is N-acetylhydroxyproline.

5. The pharmaceutical composition according to claim 4 , wherein said amino sugar is glucosamine or a salt thereof.

6. The pharmaceutical composition according to claim 5 , comprising said glycosaminoglycan or salt thereof, wherein said glycosaminoglycan is chondroitin sulfate or a salt thereof.

7. A method for treating arthritis, comprising administering the pharmaceutical composition according to claim 6 to a patient in need thereof.

8. The method according to claim 7 , wherein said arthritis is rheumatoid arthritis.

9. A food, drink or an animal feed which comprises an N-acylated hydroxyproline derivative or a salt thereof, an amino sugar or a salt thereof, and a glycosaminoglycan or a salt thereof.

10. The food, drink or the animal feed according to claim 9 , wherein said hydroxyproline is selected from the group consisting of cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and trans-3-hydroxy-D-proline.

11. The food, drink or the animal feed according to claim 9 or 10 , wherein the acyl moiety of said N-acylated hydroxyproline derivative is an acyl group having 2–23 carbon atoms.

12. The food, drink or the animal feed according to claim 11 , wherein said N-acylated hydroxyproline derivative is N-acetylhydroxyproline.

13. The food, drink or the animal feed according to claim 12 , wherein said amino sugar is glucosamine or a salt thereof.

14. The food, drink or the animal feed according to claim 13 , wherein said glycosaminoglycan is chondroitin sulfate or a salt thereof.

15. A method for treating arthritis in mammals, which comprises administering a composition comprising (I) and (II):

(I) an-N-acylated hydroxyproline derivative or a salt thereof,

(II) at least one of

(i) an amino sugar or a salt thereof, and

(ii) a glycosaminoglycan or a salt thereof

to a patient in need thereof.

16. The method according to claim 15 wherein the patient is a human.

17. The method according to claim 15 or 16 wherein said composition is administered orally.

18. The method according to claim 15 or 16 , wherein said composition comprises both (i) said amino sugar or salt thereof and (ii) said glycosaminoglycan or salt thereof.

19. The method according to claim 17 , wherein said composition comprises both (i) said amino sugar or salt thereof and (ii) said glycosaminoglycan or salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2009
From: KYOWA HAKKO KOGYO CO., LTD.
To: KYOWA HAKKO BIO CO., LTD.
Reel/Frame 022399/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2003
From: NAKAGIRI, RYUSUKE; KAMIYA, TOSHIKAZU
To: KYOWA HAKKO KOGYO CO., LTD.
Reel/Frame 014606/0798 →